2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101205
    ICI 199441 115199-84-3 99.39%
    ICI 199441 is a potent and selective κ-opioid receptor agonist. ICI 199441 can improve heart resistance to ischemia/reperfusion.
    ICI 199441
  • HY-101656
    Medroxalol 56290-94-9 99.66%
    Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.
    Medroxalol
  • HY-103263
    PSB-06126 1052089-16-3 99.86%
    PSB-06126 is a selective nucleoside triphosphate diphosphohydrolase (NTPDase) inhibitor, with the Ki values of 0.33 μM for rat NTPDase 1, 19.1 μM for NTPDase 2 and 2.22 μM for NTPDase 3, respectively. PSB-06126 acts on human NTPDase 3 with an IC50 value of 7.76 μM and a Ki value of 4.39 μM.
    PSB-06126
  • HY-103484
    GATA4-NKX2-5-IN-1 544681-96-1 99.24%
    GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC50 of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression.
    GATA4-NKX2-5-IN-1
  • HY-105858
    H-Ile-Trp-OH 13589-06-5 98.03%
    H-Ile-Trp-OH (Ile-Trp), a dipeptide, is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.7 μM. H-Ile-Trp-OH inhibits predominantly the C-domain of ACE.
    H-Ile-Trp-OH
  • HY-106612
    Abanoquil 90402-40-7 98.43%
    Abanoquil (U-K52046), an potent and selective α-1 adrenoceptor antagonist, is an anti-arrhythmic agent. Abanoquil can be used for erectile dysfunction research.
    Abanoquil
  • HY-108845
    Tenecteplase 191588-94-0
    Tenecteplase (TNK-tPA) is a modified tissue plasminogen activator. Tenecteplase is a recombinant human tissue plasminogen activator (rt-PA) that has been bioengineered to produce mutations in three gene loci. Tenecteplase (TNK-tPA) can be used in the study of acute ischemic stroke.
    Tenecteplase
  • HY-110084
    BTZO-1 99420-15-2 99.69%
    BTZO-1 binds to Macrophage migration inhibitory factor (MIF) with a Kd value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.
    BTZO-1
  • HY-113317
    L-Xylulose 527-50-4 99.80%
    L-Xylulose is an endogenous metabolite present in Blood, Cerebrospinal_Fluid and Urine that can be used for the research of Ribose 5 Phosphate Isomerase Deficiency.
    L-Xylulose
  • HY-114511
    BMS-593214 1004551-40-9 99.90%
    BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT).
    BMS-593214
  • HY-114683
    KS370G 105955-01-9 99.71%
    KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.
    KS370G
  • HY-118060
    Dipeptide 2 24587-37-9
    Dipeptide 2 (N-Valyltryptophan; Val-Trp) is a bioactive peptide with anti-aging effect and has been reported used as a cosmetic ingredient. Dipeptide 2 is an angiotensin-converting Enzyme (ACE).
    Dipeptide 2
  • HY-118941
    BAY 73-1449 693790-96-4 99.99%
    BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC50 of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure.
    BAY 73-1449
  • HY-119727
    WNK-IN-1 2125724-72-1 98.87%
    WNK-IN-1 (compound 7) is a ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor (IC50=95 nM). WNK-IN-1 can be used to regulate cardiovascular homeostasis.
    WNK-IN-1
  • HY-121936
    Yohimbic acid 522-87-2 99.09%
    Yohimbic acid is an amphoteric demethylated derivative of Yohimbine. Yohimbic acid exhibits vasodilatory action. Yohimbic acid also can be used for the research of osteoarthritis (OA).
    Yohimbic acid
  • HY-122094
    Steppogenin 56486-94-3 99.49%
    Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors.
    Steppogenin
  • HY-122365
    Inositol nicotinate 6556-11-2 98.00%
    Inositol nicotinate (Hexanicit) has vasodilating effects and can be used in research on peripheral arterial disease, showing efficacy when taken orally. Inositol nicotinate does not significantly improve triglyceride levels in mice induced by biphenyl esters.
    Inositol nicotinate
  • HY-123499
    SRA880 573984-99-3 98.22%
    SRA880 is a non-peptide and selective somatostatin sst(1) receptor antagonist. SRA880 exhibits antidepressant-like effects when in combination with Imipramine (HY-B1490A) .
    SRA880
  • HY-125643
    Pitavastatin lactone 141750-63-2 99.30%
    Pitavastatin lactone is a major metabolite of Pitavastatin in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase little metabolized in hepatic microsomes.
    Pitavastatin lactone
  • HY-133149
    Lp-PLA2-IN-3 2196245-16-4 99.94%
    Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2).
    Lp-PLA2-IN-3
Cat. No. Product Name / Synonyms Application Reactivity